|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>Aim:</b> Chimeric antigen receptor-engineered T (CAR-T) cells have gained huge success in treating hematological malignancies, yet the CD3ζ-based CAR-T therapies have not shown comparable clinical benefits in solid tumors.
|
31268375 |
2019 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CAR T cells have shown dramatic effects against blood cancers, but they have had little impact on solid tumors.
|
25583818 |
2015 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CAR-T cell therapy has achieved gratifying breakthrough in hematological malignancies and promising outcome in solid tumor as showed in various clinical trials.
|
28356156 |
2017 |
|
Hematologic Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
CAR-T therapy has shown great success treating blood cancers, but drawbacks include high manufacturing costs and potentially fatal toxicities such as cytokine release syndrome.
|
30075127 |
2018 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CAR-T therapy has achieved encouraging breakthroughs in the treatment of hematological malignancies.
|
30410941 |
2018 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CAR-T has shown promise in a number of other hematologic malignancies, and toxicities have become more manageable as its use is becoming more widespread.
|
30715612 |
2019 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CAR-T cell-based immunotherapy has shown great promise in clinical trials for the treatment of hematological malignancies.
|
31814915 |
2019 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Adoptive transfer of autologous CAR-T cells can induce durable remissions in patients with relapsed/refractory hematologic malignancies.
|
29909917 |
2018 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Although CAR T cell therapy mediates robust responses in patients with hematological malignancies, this approach has been less effective for treating patients with solid tumors.
|
30842774 |
2019 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Although CAR T-cell therapy has demonstrated tremendous clinical efficacy especially in hematological malignancies, severe treatment-associated toxicities still compromise the widespread application of this innovative technology.
|
31414180 |
2019 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Application of chimeric antigen receptor T (CAR-T) cell therapy has recently achieved excellent clinical outcome in patients, especially those with CD19-positive hematologic malignancies.
|
29769134 |
2018 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Because CAR-T therapy has shown great success in treating CD19-positive hematological malignancies, its application has been explored in the treatment of solid tumors, such as liver cancer.
|
29861325 |
2018 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cancer immunotherapy by chimeric antigen receptor-modified T (CAR-T) cells has shown exhilarative clinical efficacy for hematological malignancies.
|
31754328 |
2019 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CD19, CD20 chimeric antigen receptor T (CAR T) cell therapy has shown promising results for the treatment of relapsed or refractory hematological malignancies.
|
28128714 |
2017 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Chimeric antigen receptor T (CAR-T) cells have demonstrated promising results against hematological malignancies, but have encountered significant challenges in translation to solid tumors.
|
27145250 |
2016 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Chimeric antigen receptor T (CAR-T) cells have shown promising efficacy in treatment of hematological malignancies, but its applications in solid tumors need further exploration.
|
28366766 |
2017 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Chimeric antigen receptor T (CAR-T) cells are a promising new treatment for patients with relapsed or refractory hematologic malignancies, including lymphoma.
|
30841880 |
2019 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Chimeric antigen receptor T (CAR-T) cell therapy is a novel cellular immunotherapy that is widely used to treat hematological malignancies, including acute leukemia, lymphoma, and multiple myeloma.
|
31571160 |
2019 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Chimeric antigen receptor-engineered T (CAR-T)-cell therapy holds significant promise for the treatment of hematological malignancies, especially for B-cell leukemia and lymphoma.
|
31432594 |
2019 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Chimeric antigen receptor-modified (CAR-modified) T cells have shown promising therapeutic effects for hematological malignancies, yet limited and inconsistent efficacy against solid tumors.
|
29769444 |
2018 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Chimeric antigen receptor-modified T (CAR-T) cells have achieved significant success in the treatment of several hematological malignancies.
|
31221182 |
2019 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Chimeric Antigen Receptor-T (CAR-T) cell immunotherapy has produced dramatic responses in hematologic malignancies.
|
30760795 |
2019 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Clinical success of autologous CD19-directed chimeric antigen receptor T cells (CAR Ts) in acute lymphoblastic leukemia and non-Hodgkin lymphoma suggests that CAR Ts may be a promising therapy for hematological malignancies, including multiple myeloma.
|
31005597 |
2019 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Currently, chimeric antigen receptor T-cell (CAR-T) immunotherapy has achieved numerous breakthroughs in the treatment of hematological malignancies, including relapsed or refractory lymphoblastic leukemia and refractory large B-cell lymphoma.
|
30659408 |
2019 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Despite its revolutionary success in hematological malignancies, chimeric antigen receptor T (CAR-T) cell therapy faces disappointing clinical results in solid tumors.
|
30734529 |
2019 |